Sanofi EU antitrust settlement and Shkreli contempt case lead pharma news
Sanofi has settled a European Union antitrust investigation, and U.S. regulators asked a court to hold Martin Shkreli in contempt for allegedly violating an order that bars him from the pharmaceutical industry. The roundup also covers other biopharma news.
The two items reflect ongoing regulatory scrutiny of pharmaceutical-sector conduct. Sanofi’s settlement resolves an EU antitrust matter, while U.S. regulators are seeking contempt proceedings against Martin Shkreli over an alleged breach of an order excluding him from the pharmaceutical industry. The roundup also includes other biopharma news. Together, these developments illustrate how competition and compliance issues continue to feature in drug-industry coverage.
The Sanofi settlement could reinforce expectations that drugmakers face close antitrust oversight in Europe, which may affect competition and, indirectly, medicine access. The Shkreli contempt request may signal that regulators could pursue alleged violations of industry bans, potentially shaping compliance incentives for individuals and companies. Patients and consumers could be affected if enforcement changes market behavior, though the immediate consequences remain uncertain.